Inclusion Criteria:

- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
0 - 2

- Patients enrolled into phase Ib may be enrolled with evaluable disease only. Patients
enrolled into the phase II expansion must have at least one measurable lesion as
defined by RECIST 1.1 criteria.

- Patients must have adequate organ function, as defined by the following parameters:

1. Bone marrow:

- Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L

- Hemoglobin (Hgb) ≥ 9 g/dL

- Platelets ≥ 75 x 109/L without transfusions within 21 days before 1st
treatment

2. Serum creatinine ≤1.5 ULN

3. Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN)

4. Aspartate Aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT]) and ALT (SGPT) ≤ 3 x ULN, except in patients with tumor involvement
of the liver who must have AST and ALT ≤ 5 x ULN

Exclusion Criteria:

- Symptomatic brain metastases. Patients previously treated or untreated for brain
metastases that are asymptomatic in the absence of corticosteroid therapy are allowed
to enroll. Brain metastases must be stable for at least 2 weeks after completion of
the definitive therapy with verification by imaging (e.g. brain MRI completed at
screening demonstrating no current evidence of progressive brain metastases).

- Impaired cardiac function or clinically significant cardiac diseases, including any
of the following:

1. Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated
acquisition scan (MUGA) or echocardiogram (ECHO)

2. Congenital long QT syndrome or family history of unexpected sudden cardiac death

3. QTc corrected with Frederica's or Bazett's formula (QTcF) >450 ms for males and
>470 ms for females on screening ECG

4. Any other clinically significant heart disease such as angina pectoris, resting
bradycardia, left bundle branch block, ventricular tachyarrhythmia, unstable
atrial fibrillation, branch block or hemi block, acute myocardial infarction or
any heart disease that requires the use of a cardiac pacemaker or implantable
cardioverter defibrillator

- Patients who are currently receiving treatment with agents that are known to cause
QTc prolongation in humans. See investigators brochure for a complete list of agents
that are known to cause QTc prolongation in humans.

- Patients who are currently receiving treatment with agents that are metabolized
predominantly through CYP3A4 and that have a narrow therapeutic window.

- Patients with concurrent severe and/or uncontrolled concurrent medical conditions
that could compromise participation in the study (e.g., uncontrolled hypertension
and/or diabetes mellitus, clinically significant pulmonary disease, clinically
significant neurological disorder, active or uncontrolled infection)

- Current evidence of retinal disease; history of CSR, RVO or ophthalmology as assessed
by ophthalmologic examination at baseline that would be considered a risk factor for
CSR/RVO (e.g., optic disc cupping, visual field defects, IOP > 21 mm Hg)

Other protocol related inclusion/exclusion criteria may apply.